Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Goal-directed Fluid Therapy During Deep Inferior Epigastric Perforator (DIEP) Free Flap Breast Reconstruction
NCT06080178 · Algemeen Ziekenhuis Maria Middelares · PHASE4 · terminated · last registry update 2026-10-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The planned interim analysis revealed greater variability than expected, requiring a larger sample size. Given the limited eligible population, recruitment was deemed infeasible within a reasonable timeframe, leading to study termination.” | – | Registry record, Algemeen Ziekenhuis Maria Middelares |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-14Also stopped (terminated): Yale University, Phenylephrine + Norepinephrine (NCT04218773)
- 2026-10-09Also stopped (suspended): Ergun Y. Uc, Terazosin 5 MG + Placebo (NCT07464028)
- 2026-10-08Results posted on the registry: Opus Genetics, Inc, Phentolamine Mesylate Ophthalmic Solution 1.0% + Phentolamine Mesylate Ophthalmic Solution 0.5% (NCT01703559)
- 2026-10-07Also stopped (withdrawn): Nandakumar Narayanan, Terazosin Hydrochloride (NCT07288450)
- 2026-10-05Results posted on the registry: Ankara City Hospital Bilkent, Sevoflurane (Volatile Anesthetic) + Propofol 1% (NCT07092046)
- 2026-09-21Also stopped (withdrawn): University Ghent, a drug against ADRA1A (NCT06810674)
- 2026-08-18Results posted on the registry: Opus Genetics, Inc, phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist + Placebo (NCT06349759)
- 2026-08-17Results posted on the registry: Opus Genetics, Inc, 0.75% phentolamine ophthalmic solution + Placebo (NCT06542497)
- 2026-04-27Results posted on the registry: University of Pennsylvania, Phentolamine + Propranolol (NCT03079921)
- 2025-12-23Phase 3 first posted: Ain Shams University, Balanced anesthesia + Lidocaine spray (NCT07299630)
- 2025-12-17Results posted on the registry: University of Edinburgh, a drug against ADRA1A (NCT04614168)
- 2025-12-11Also stopped (terminated): Hopital Charles Nicolle, Ephedrine (6 mg boluses) + Norepinephrine (10 µg boluses) (NCT07259655)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision